Corvus Pharmaceu Stock Price, News & Analysis

Corvus Pharmaceuticals (NASDAQ: CRVS) announced on October 2, 2025 the appointment of David Moore to its Board of Directors. Mr. Moore is Executive Vice President, US Operations and President at Novo Nordisk Inc., with 27 years of industry experience across strategy, commercial, market access, business development and private equity. Management expects his commercial and corporate development experience to support advancement of Corvus’ ITK inhibitor pipeline.

Corvus Pharmaceuticals (NASDAQ:CRVS) reported significant progress in its clinical trials and financial results for Q2 2025. The company's lead drug candidate soquelitinib showed promising results in Phase 1 trials for atopic dermatitis, with cohort 3 achieving a 64.8% mean EASI reduction compared to 34.4% for placebo. The company is advancing multiple clinical programs, including a Phase 3 trial for peripheral T cell lymphoma (PTCL) and collaboration with NIAID for ALPS treatment.

Financially, Corvus strengthened its position with warrant exercises providing $35.7 million in proceeds during Q2, ending the quarter with $74.4 million in cash. The company expects its cash runway to extend into Q4 2026. R&D expenses increased to $7.9 million, up from $4.1 million in Q2 2024, with a net loss of $8.0 million.

Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results and business update conference call for August 7, 2025 at 4:30 pm ET.

Investors can access the call via telephone at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations website, with a replay accessible for 90 days following the presentation.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its Chinese partner Angel Pharmaceuticals received IND approval from China's NMPA to begin a Phase 1b/2 clinical trial of soquelitinib for treating moderate-to-severe atopic dermatitis.

The trial will evaluate 12-week dosing across multiple cohorts, with Phase 1b enrolling 48 patients across two cohorts testing different dosing regimens. Patient enrollment is expected to begin in Q3 2025, with Phase 1b data anticipated in 2026. The study will be led by Dr. Yuling Shi, a prominent dermatology expert from Shanghai Skin Disease Hospital.

Corvus, which co-founded Angel Pharma to develop its pipeline in greater China, has licensed the rights for soquelitinib development, manufacturing, and commercialization in the region to Angel Pharma.

Corvus Pharmaceuticals (NASDAQ: CRVS) announced the presentation of preclinical data for soquelitinib, their lead ITK inhibitor, at the EULAR 2025 Congress in Barcelona. The presentation focuses on the drug's potential to treat systemic sclerosis, with data suggesting it may prevent lung damage, inflammation, and pulmonary hypertension associated with the condition. Dr. Gonçalo Boleto from Centro Académico de Medicina de Lisboa will present the research, which was selected as a top 10 abstract by EMEUNET. While Corvus's primary focus remains on soquelitinib's Phase 3 trial in peripheral T cell lymphoma and Phase 1 trial in atopic dermatitis, the company may explore systemic sclerosis applications through future clinical trials or partnerships.

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 clinical trial data for soquelitinib in treating moderate to severe atopic dermatitis. Cohort 3 (200mg twice daily) showed superior results compared to cohorts 1-2, with a 64.8% mean EASI score reduction vs 54.6% for cohorts 1-2 and 34.4% for placebo at day 28. The drug demonstrated statistically significant improvement (p=0.036) and earlier response onset, with itch reduction observed as early as day 8. Safety profile was favorable with no dose-limiting toxicities. Notably, 50% of evaluable Cohort 3 patients achieved clinically meaningful itch reduction. The company has initiated an extension study with an 8-week treatment period at the Cohort 3 dose level to explore longer-duration benefits.

Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York. The company's leadership team will deliver a corporate overview presentation on Thursday, June 5, from 9:20-9:50 am ET and conduct one-on-one meetings with investors. A webcast of the presentation will be available live and accessible for 90 days after the event through the investor relations section of Corvus's website.

<p><b>Corvus Pharmaceuticals (CRVS)</b> reported Q1 2025 financial results and provided key business updates. The company's lead drug <b>soquelitinib</b> showed favorable safety and efficacy in Phase 1 trials for atopic dermatitis, with cohort 3 (200mg twice daily) demonstrating earlier and deeper responses compared to lower doses. The company received <b>$31.3 million from early warrant exercises</b> by stockholders at $3.50 per share.</p><p>Financial highlights include cash position of <b>$44.2 million</b> as of March 31, 2025, with operations funded into Q4 2026. Q1 2025 showed <b>net income of $15.2 million</b>, including a $25.1 million warrant liability gain. R&D expenses increased to <b>$7.5 million</b>, up from $4.1 million in Q1 2024.</p>

Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis. The trial showed favorable safety and efficacy profiles, with Cohort 3 (200mg twice daily) demonstrating earlier and deeper responses compared to Cohorts 1-2. Key findings include: - Cohort 3 achieved 71.1% reduction in mean EASI score vs 42.1% for placebo - Combined Cohorts 1-2 showed 54.6% reduction vs 30.6% for placebo - Treatment was well-tolerated with no dose-limiting toxicities - Positive biomarker results showing reduction in inflammatory cytokines Based on these results, Corvus has amended the trial protocol to evaluate an additional 24 patients at 200mg twice daily for an extended 8-week treatment period. The company plans to initiate a Phase 2 trial by year-end.